Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vactosertib with Paclitaxel and Ramucirumab in Metastatic Gastric Cancer
NCT04656002Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of vactosertib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Samsung Medical Center. Primary endpoint: Objective Response Rate up to 24 months. Status: unknown.
02
Drugs
vactosertib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04656002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04656002.